You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:


Last Updated: September 26, 2023

Details for Patent: 9,555,001

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,555,001 protect, and when does it expire?

Patent 9,555,001 protects JENTADUETO XR and is included in one NDA.

Protection for JENTADUETO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in sixteen countries.

Summary for Patent: 9,555,001
Title:Pharmaceutical composition and uses thereof
Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Inventor(s): Ito; Masanori (Hyogo, JP), Egusa; Kenji (Biberach an der Riss, DE), Kleinbeck; Kyle (Brooklyn, NY), Messerschmid; Roman (Ulm, DE), Schneider; Peter (Ulm-Einsingen, DE), Voleti; Venkata (Mason, OH)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:13/785,365
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,555,001

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,555,001

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 090269 ⤷  Try a Trial
Australia 2013229538 ⤷  Try a Trial
Canada 2866421 ⤷  Try a Trial
Chile 2014002325 ⤷  Try a Trial
China 104220049 ⤷  Try a Trial
Eurasian Patent Organization 201400986 ⤷  Try a Trial
European Patent Office 2822544 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.